Zarife Sahenk

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8605158/publications.pdf

Version: 2024-02-01

59	4,174	156536	169272
papers	citations	32	56
		h-index	g-index

61	61	61	4526
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	AAV1.NT-3 gene therapy for X-linked Charcotâ€“Marieâ€“Tooth neuropathy type 1. Gene Therapy, 2022, 29, 127-137.	2.3	22
2	Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1. Molecular Therapy - Methods and Clinical Development, 2021, 22, 401-414.	1.8	9
3	Unmet needs and evolving treatment for limb girdle muscular dystrophies. Neurodegenerative Disease Management, 2021, 11, 411-429.	1.2	22
4	AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in GarsP278KY/+ mice. Brain Communications, 2021, 3, fcab252.	1.5	15
5	Gene therapy to promote regeneration in Charcot-Marie-Tooth disease. Brain Research, 2020, 1727, 146533.	1.1	21
6	Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy. JAMA Neurology, 2020, 77, 1122.	4.5	226
7	Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine (United States), 2019, 98, e15858.	0.4	61
8	A Novel De Novo Heterozygous SCN4a Mutation Causing Congenital Myopathy, Myotonia and Multiple Congenital Anomalies. Journal of Neuromuscular Diseases, 2019, 6, 467-473.	1.1	9
9	Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion. Human Gene Therapy, 2019, 30, 794-801.	1.4	34
10	PUMILIO hyperactivity drives premature aging of Norad-deficient mice. ELife, 2019, 8, .	2.8	65
11	Autoâ€antibodies Targeting Components of Sarcolemma Repair Represent a Pathogenic Mechanism in Idiopathic Immune Myopathies. FASEB Journal, 2019, 33, 701.2.	0.2	0
12	Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Molecular Therapy - Methods and Clinical Development, 2018, 8, 121-130.	1.8	44
13	AAV1.NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model. Gene Therapy, 2018, 25, 129-138.	2.3	40
14	Efficacy of exogenous pyruvate in Trembler^J mouse model of Charcotâ€Marieâ€Tooth neuropathy. Brain and Behavior, 2018, 8, e01118.	1.0	12
15	Eteplirsen treatment for Duchenne muscular dystrophy. Neurology, 2018, 90, e2146-e2154.	1.5	175
16	Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Molecular Therapy, 2017, 25, 870-879.	3.7	84
17	A novel p.T139M mutation in HSPB1 highlighting the phenotypic spectrum in a family. Brain and Behavior, 2017, 7, e00774.	1.0	12
18	Clinical trials of exon skipping in Duchenne muscular dystrophy. Expert Opinion on Orphan Drugs, 2017, 5, 683-690.	0.5	14

#	Article	IF	Citations
19	Impaired regeneration in calpain-3 null muscle is associated with perturbations in mTORC1 signaling and defective mitochondrial biogenesis. Skeletal Muscle, 2017, 7, 27.	1.9	29
20	Defective membrane fusion and repair inAnoctamin5-deficient muscular dystrophy. Human Molecular Genetics, 2016, 25, 1900-1911.	1.4	88
21	AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models. Annals of Clinical and Translational Neurology, 2015, 2, 256-270.	1.7	78
22	Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy. Journal of Neuromuscular Diseases, 2015, 2, 185-192.	1.1	34
23	A slowly progressive form of limbâ€girdle muscular dystrophy type 2C associated with founder mutation in the SGCG gene in Puerto Rican Hispanics. Molecular Genetics & Genomic Medicine, 2015, 3, 92-98.	0.6	10
24	A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy. Molecular Therapy, 2015, 23, 192-201.	3.7	193
25	AAV1.NT-3 Gene Therapy for Charcotâ€“Marieâ€“Tooth Neuropathy. Molecular Therapy, 2014, 22, 511-521.	3.7	86
26	VIP-expressing Dendritic Cells Protect Against Spontaneous Autoimmune Peripheral Polyneuropathy. Molecular Therapy, 2014, 22, 1353-1363.	3.7	13
27	Vascular Delivery of rAAVrh74.MCK.GALGT2 to the Gastrocnemius Muscle of the Rhesus Macaque Stimulates the Expression of Dystrophin and Laminin Î±2 Surrogates. Molecular Therapy, 2014, 22, 713-724.	3.7	61
28	Impaired regeneration in LGMD2A supported by increased PAX7â€positive satellite cell content and muscleâ€specific microrna dysregulation. Muscle and Nerve, 2013, 47, 731-739.	1.0	21
29	Update on the Treatment of Duchenne Muscular Dystrophy. Current Neurology and Neuroscience Reports, 2013, 13, 332.	2.0	52
30	Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Human Molecular Genetics, 2013, 22, 4929-4937.	1.4	53
31	Pathogenesis of Autosomal Dominant Hereditary Spastic Paraplegia (SPG6) Revealed by a Rat Model. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1016-1028.	0.9	17
32	Mutant HSPB1 overexpression in neurons is sufficient to cause age-related motor neuronopathy in mice. Neurobiology of Disease, 2012, 47, 163-173.	2.1	35
33	The Muscular Dystrophies: Distinct Pathogenic Mechanisms Invite Novel Therapeutic Approaches. Current Rheumatology Reports, 2011, 13, 199-207.	2.1	14
34	Gentamicinâ€induced readthrough of stop codons in duchenne muscular dystrophy. Annals of Neurology, 2010, 67, 771-780.	2.8	238
35	Sustained alphaâ€sarcoglycan gene expression after gene transfer in limbâ€girdle muscular dystrophy, type 2D. Annals of Neurology, 2010, 68, 629-638.	2.8	214
36	Dystrophin Immunity in Duchenne's Muscular Dystrophy. New England Journal of Medicine, 2010, 363, 1429-1437.	13.9	546

#	Article	IF	Citations
37	TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in TremblerJ mice. Experimental Neurology, 2010, 224, 495-506.	2.0	31
38	Overexpression ofGalgt2in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. American Journal of Physiology - Cell Physiology, 2009, 296, C476-C488.	2.1	78
39	Neurotrophin-3 deficient Schwann cells impair nerve regeneration. Experimental Neurology, 2008, 212, 552-556.	2.0	26
40	Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4318-4322.	3.3	235
41	Pilot Clinical Trial of NT-3 in CMT1A Patients. Progress in Neurotherapeutics and Neuropsychopharmacology, 2007, 2, 97-108.	0.0	7
42	Neurotrophins and Peripheral Neuropathies. Brain Pathology, 2006, 16, 311-319.	2.1	13
43	Evidence for impaired axonal regeneration in PMP22 duplication: studies in nerve xenografts. Journal of the Peripheral Nervous System, 2003, 8, 116-127.	1.4	16
44	Pathogenesis of X-Linked Charcot-Marie-Tooth Disease: Differential Effects of Two Mutations in Connexin 32. Journal of Neuroscience, 2003, 23, 10548-10558.	1.7	53
45	Intracellular Processing and Toxicity of the Truncated Androgen Receptor: Nuclear Congophilia-Associated Cell Death. Journal of Neuropathology and Experimental Neurology, 2000, 59, 652-663.	0.9	1
46	Abnormal Schwann Cell-Axon Interactions in CMT Neuropathies: The Effects of Mutant Schwann Cells on the Axonal Cytoskeleton and Regeneration-Associated Myelination. Annals of the New York Academy of Sciences, 1999, 883, 415-426.	1.8	37
47	Alterations in Nodes of Ranvier and Schmidt-Lanterman Incisures in Charcot-Marie-Tooth Neuropathies. Annals of the New York Academy of Sciences, 1999, 883, 508-512.	1.8	7
48	Effects of PMP22 duplication and deletions on the axonal cytoskeleton. Annals of Neurology, 1999, 45, 16-24.	2.8	93
49	Novel single base polymorphisms and rare sequence variants in the laminin ?2-chain coding region detected by RNA/SSCP analysis. Human Mutation, 1999, 13, 174-174.	1.1	0
50	Abnormalities in the axonal cytoskeleton induced by a connexin32 mutation in nerve xenografts. , 1998, 51, 174-184.		67
51	A novel PMP22 point mutation causing HNPP phenotype. Neurology, 1998, 51, 702-707.	1.5	41
52	Fate of Schwann Cells in CMT1A and HNPP: Evidence for Apoptosis. Journal of Neuropathology and Experimental Neurology, 1998, 57, 635-642.	0.9	34
53	Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy. New England Journal of Medicine, 1995, 333, 832-838.	13.9	489
54	Gene delivery to spinal motor neurons. Brain Research, 1993, 606, 126-129.	1.1	25

#	Article	IF	Citations
55	Alterations in slow transport kinetics induced by estramustine phosphate, an agent binding to microtubule-associated proteins. Journal of Neuroscience Research, 1992, 32, 481-493.	1.3	12
56	Studies on the pathogenesis of vincristine-induced neuropathy. Muscle and Nerve, 1987, 10, 80-84.	1.0	105
57	Axonal tubulin and microtubules: Morphologic evidence for stable regions on axonal microtubules. Cytoskeleton, 1987, 8, 155-164.	4.4	55
58	Axoplasmic transport in zinc pyridinethione neuropathy: Evidence for an abnormality in distal turn-around. Brain Research, 1980, 186, 343-353.	1.1	57
59	Ultrastructural Study of Zinc Pyridinethione-Induced Peripheral Neuropathy. Journal of Neuropathology and Experimental Neurology, 1979, 38, 532-550.	0.9	45